Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2003 3
2004 1
2010 4
2011 2
2012 3
2013 3
2014 6
2015 8
2016 16
2017 21
2018 20
2019 16
2020 20
2021 17
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

126 results
Results by year
Filters applied: . Clear all
Page 1
Treating Leukemia in the Time of COVID-19.
Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Paul S, et al. Among authors: dabaja bs. Acta Haematol. 2021;144(2):132-145. doi: 10.1159/000508199. Epub 2020 May 11. Acta Haematol. 2021. PMID: 32392559 Free PMC article. Review.
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Pinnix CC, et al. Among authors: dabaja bs. Blood Adv. 2020 Jul 14;4(13):2871-2883. doi: 10.1182/bloodadvances.2020001837. Blood Adv. 2020. PMID: 32589728 Free PMC article.
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Jabbour E, et al. Among authors: dabaja bs. Cancer. 2021 Jun 15;127(12):2025-2038. doi: 10.1002/cncr.33469. Epub 2021 Mar 19. Cancer. 2021. PMID: 33740268 Free article.
ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma.
Dabaja BS, Ng AK, Terezakis SA, Plastaras JP, Yunes M, Wilson LD, Yang J, Gunther JR, Specht L, Yahalom J. Dabaja BS, et al. Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):977-978. doi: 10.1016/j.ijrobp.2020.05.063. Epub 2020 Aug 4. Int J Radiat Oncol Biol Phys. 2020. PMID: 32768256 No abstract available.
In Reply to Scarpelli et al.
Specht L, Wong JYC, Filippi AR, Dabaja BS, Yahalom J. Specht L, et al. Among authors: dabaja bs. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1396. doi: 10.1016/j.ijrobp.2020.07.2315. Epub 2020 Nov 18. Int J Radiat Oncol Biol Phys. 2020. PMID: 33220231 No abstract available.
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.
Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. Winkfield KM, et al. Among authors: dabaja bs. Oncology (Williston Park). 2016 Dec 15;30(12):1099-103, 1106-8. Oncology (Williston Park). 2016. PMID: 27987203 Free PMC article. Review.
126 results